Introduction
============

Liver cancer is the fifth most common cancer type in adult males and ninth in female worldwide in 2018; furthermore, liver cancer is the third leading cause of cancer-associated mortalities globally in 2018 ([@b1-or-41-04-2075]), with \~782,000 deaths annually globally ([@b2-or-41-04-2075],[@b3-or-41-04-2075]). Frequent intrahepatic spread and extrahepatic metastasis are the primary factors of mortality during the initial diagnosis, and there is a \~70% 5-year recurrence rate of tumor recurrence ([@b4-or-41-04-2075]). Patients with liver cancer are frequently diagnosed at an advanced stage of the disease and lose the possibility of an effective treatment with surgical resection and liver transplantation ([@b5-or-41-04-2075]). Therefore, chemotherapy remains the only approach for treating patients with advanced liver cancer. Currently, the exact molecular mechanisms underlying liver cancer development remain unclear. Therefore, it is of utmost importance for the identification of reliable biomarkers for a precise prognosis, and development of more effective therapeutic approaches for individualized treatment of patients with liver cancer ([@b6-or-41-04-2075],[@b7-or-41-04-2075]).

Opa interacting protein 5 (OIP5) encodes a protein which appertain to cancer/testis antigens (CTAs) ([@b8-or-41-04-2075]). The *OIP5* gene localizes on chromosome 15 ([@b8-or-41-04-2075]). OIP5 protein combined with C21orf45 and M18 binding protein 1 forms a complex, and then accumulates specifically at telophase-G1 centromeres, which is consequently essential for the structure and function of the centromere/kinetochore ([@b9-or-41-04-2075]). This protein also regulates the cell cycle exit via interacting with the retinoblastoma protein through the E2F-Rb pathway ([@b10-or-41-04-2075]).

Ectopic OIP5 expression is identified in a number of cancer types. For example, increased OIP5 expression is associated with advanced tumor stage and reduced patients overall survival time with clear cell renal cell carcinoma ([@b11-or-41-04-2075]). OIP5 is also highly expressed in samples from patients with colorectal ([@b12-or-41-04-2075]) and gastric cancer ([@b13-or-41-04-2075]), and acute myeloid leukemia ([@b14-or-41-04-2075]). Increased OIP5 expression is significantly associated with poor prognosis of patients with lung and esophageal cancer. Furthermore, it is also a potential target for the development of prognostic biomarkers and cancer therapy ([@b15-or-41-04-2075]).

OIP5 upregulation induces AKT activation via mammalian target of rapamycin complex 2 (mTORC2) and p38/phosphatase and tensin homolog signaling pathways, and activates β-catenin signaling through enhancing its nuclear translocation by phosphorylating β-catenin and glycogen synthase kinase-3β ([@b16-or-41-04-2075]). Additionally, OIP5 downregulation inhibits OIP5 oncogenic signaling through its action on mTORC1 and β-catenin pathways ([@b16-or-41-04-2075]). OIP5 expression is significantly increased in GIII/IV (Edmondson grade) hepatocellular carcinoma (HCC), compared with in GI/II HCC, through the analysis of GSE36411 dataset derived from the Gene Expression Omnibus database ([@b16-or-41-04-2075]).

Until now, despite all these studies aforementioned, no report is available concerning OIP5 expression status and biological functions in human liver cancer, as well as the precise OIP5 mechanism in liver cancer. Therefore, OIP5 protein expression in HCC specimens was detected in the present study. The association between its expression and clinicopathological characteristics in patients with HCC was also investigated. The results demonstrated that OIP5 downregulation influenced cell proliferation, apoptosis, colony formation and the cell cycle in liver cancer cell lines, as well as cell signaling in Huh7 cells. These data may provide beneficial information regarding liver cancer pathogenesis, and reveal a potential biomarker for liver cancer therapy.

Materials and methods
=====================

### Patients and tissue specimens

From September 2007 to March 2008, a total of 75 Chinese Han patients with recently diagnosed primary HCC and who had received surgical resection of HCC neoplasm were recruited by the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). The ages of the patients at diagnosis ranged from 34--63 years, with a median age of 46 years. The clinical diagnosis of HCC was based on the National Comprehensive Cancer Network clinical practice guidelines in oncology and histopathological examination ([@b3-or-41-04-2075]). Liver samples were specimens classified as a carcinoma or para-carcinoma. Subsequently, clinical samples were fixed in 4% formalin overnight, dehydrated in graded ethanol (70, 80, 90, 95 and 100%) and paraffin-embedded at room temperature. Following this, 5 µm-thick sections were obtained using a Microm HM 355S microtome, and then mounted on Superfrost Plus slides (both from Thermo Fisher Scientific, Inc., Waltham, MA, USA). Hematoxylin and eosin staining was performed according to the protocol of the Department of Pathology at the First Affiliated Hospital of Nanjing Medical University ([@b17-or-41-04-2075]). HCC and non-tumor tissues histologically were confirmed by two pathologists who were blind to the patients\' information. Data for the age at diagnosis, sex, tumor size, pathological grade and tumor-node-metastasis (TNM) stage were obtained and listed in [Table I](#tI-or-41-04-2075){ref-type="table"} ([@b18-or-41-04-2075],[@b19-or-41-04-2075]).

The present study was performed according to the World Medical Association Declaration of Helsinki on ethical principles for medical research involving human subjects. All research procedures were approved by the Research Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. All research subjects provided signed written informed consent. The clinical outcomes of HCC were recorded until April 2018.

### Immunohistochemical (IHC) staining

Tissue sections (5-µm) were heated at 60°C, deparaffinized, and hydrated by successive washes in xylene 3 times, graded by 100, 95 and 70% ethanol, and then PBS. OIP5 antigen was recovered through incubation with 0.1 mol/l citrate buffer (pH 6.0; Abcam, Cambridge, UK) for 30 min at 95°C. Slides were then washed with PBS three times and incubated at room temperature with 3% (v/v) H~2~O~2~ for 10 min to quench endogenous peroxidase activity. Following an additional three washes with PBS, the slides were blocked against non-specific epitopes via incubation with PBS containing 10% (w/v) normal goat serum and 1% (w/v) bovine serum albumin (Abcam) for 30 min at room temperature. Slides were subsequently incubated overnight at 4°C with mouse anti-human OIP5 monoclonal antibody (1:1,000 dilution; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; cat no. SAB1407138), and washed with PBS three times. Slides were labeled with a biotinylated goat anti-mouse secondary antibody (ready for use; OriGene Technologies, Inc., Beijing, China; cat no. SP9002) for 30 min at room temperature, and washed with PBS three times. Subsequently, slides were incubated with horseradish peroxidase-labeled streptavidin (ready for use; OriGene Technologies, Inc.; cat no. SP9002) for 30 min at room temperature, and washed with PBS three times. Finally, the enzymatic reaction was triggered using 3,3′-diaminobenzidine (Sangon Biotech Co., Ltd., Shanghai, China) for 5 min. Slides were counter stained with hematoxylin (Sigma-Aldrich; Merck KGaA) for 30 sec at room temperature and washed with PBS for 5 min, and then examined under an optical microscope (magnification, ×400). Using Image Pro-Plus v6.0 (Media Cybernetics Corporation, Arrendale, PA, USA) and the following formula: IHC staining score = intensity score × positive rate score, IHC staining area of each slide was analyzed and quantified. Intensity score was scored as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive) and 3 (strongly positive). Positive rate score was scored as follows: Negative, 1--25; 26--50; 51--75; and 76--100%, which represented 0, 1, 2, 3 and 4, respectively. Finally, slides with an IHC staining score of 0--5 and 6--12 were defined as OIP5 low and high expression, respectively.

In order to analyze OIP5 mRNA differential expression in liver cancer and paired liver tissues, the online database Gene Expression Profiling Interactive Analysis (GEPIA; <http://gepia.cancer-pku.cn/index.html>) was used. Additionally, in order to deduce the association between OIP5 mRNA differential expression in liver cancer and normal liver tissues, and to produce an overall survival rate curve, the online database Kaplan-Meier Plotter (<http://kmplot.com/analysis/index.php?p=service&cancer=liver_rnaseq>) ([@b20-or-41-04-2075]) was also employed.

### Cell culture

Human liver cancer cell lines HepG2, Hep3B, Huh7, human embryonic kidney (HEK) 293T cells and primary human hepatocyte (PHH) cells were purchased from the Shanghai Cell Bank of Chinese Academy of Science (Shanghai, China). Cell lines were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 1% penicillin and streptomycin solution (all from Gibco; Thermo Fisher Scientific, Inc.), and incubated at 37°C in a 5% CO~2~ humidified atmosphere. All experiments were executed using cells at a confluence \>75%. HepG2, Hep3B, Huh7 and PHH cells were harvested and used for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. 293T cells were used as packaging host for production of lentiviruses. HepG2 and Huh7 cells were used for an MTT assay, colony formation assay, apoptosis assay and microarray analysis after being transfected with pGCSIL-shOIP5 or pGCSIL-shCtrl lentivirus.

Lentiviral short hairpin RNA (shRNA) vector construction and cell transfection. OIP5 knockdown was performed using shRNA against human OIP5 gene (GenBank accession no. NM_007280) designed from the full-length OIP5 sequence and synthesized by Shanghai GeneChem Co., Ltd. (Shanghai, China). The OIP5 gene shRNA sequence was as follows: 5′-CTACCTCTGAAGGCTACACTT-3′, while the scramble sequence was the following: 5′-TTCTCCGAACGTGTCACGT-3′. Knockdown efficiency was tested using stem-loop oligonucleotides synthesized and inserted into a pGCSIL-GFP vector (Shanghai GeneChem Co., Ltd.), which was termed pGCSIL-shOIP5. pGCSIL-GFP was used as negative-control and was termed pGCSIL-shCtrl. Lentivirus particles were packaged as previously described ([@b21-or-41-04-2075]). Briefly, the lentiviral particles were produced by co-transfection of pGCSIL-shOIP5/pGCSIL-shCtrl into 293T cells using a pHelper system (Shanghai GeneChem Co., Ltd.), according to the manufacturer\'s protocols. Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 11668019) was used according to the manufacturers protocols to transfect 1 µg/well plasmid into the cells. Lentiviruses were harvested at 48 h post-transfection.

Huh7 and HepG2 cells (5×10^4^ cells/well) were seeded into 6-well plates and transfected with pGCSIL-shOIP5 lentivirus or pGCSIL-shCtrl at a multiplicity of infection of 20, according to the aforementioned protocol. Cells were incubated in a 5% CO~2~ humidified incubator at 37°C. After 72 h, cells were observed under a fluorescence microscope (MicroPublisher™ 3.3RTV; Olympus Corporation, Tokyo, Japan) to evaluate their health status. After 5 days, knockdown efficiency was examined using western blotting and RT-qPCR as subsequently described.

### RT-qPCR

Total RNA was separated from dissected tumor and non-tumor tissues, and three cell lines, using the TRIzol^®^ reagent (Sangon Biotech Co., Ltd.), based on the manufacturer\'s protocols. RT was executed using 2 µg total RNA, 1 µl (200 units) RT-PCR SuperScript II (Invitrogen; Thermo Fisher Scientific, Inc.) and 50 µM decamer at 37°C for 50 min. Specific primers targeting OIP5 were designed by Shanghai GeneChem Co., Ltd. as follows: 5′-TGGCATTGAAGGTTCACTCA-3′ (forward) and 5′-AGGGCAGCATGGGTAGAATA-3′ (reverse), with a product length of 189 bp. RT-qPCR was performed by SYBR^®^ Master Mix Kit (Takara Biotechnology Co., Ltd., Dalian, China) on a Mx3000P qPCR system (Agilent Technologies, Inc., Santa Clara, CA, USA) and LightCycler 480 (Roche Diagnostics, Indianapolis, IN, USA). The housekeeping gene GAPDH was used for normalization. Data were calculated using the Pfaffl method ([@b22-or-41-04-2075]). PCR primers used for validating the microarray data are listed in [Table II](#tII-or-41-04-2075){ref-type="table"}. The thermal profile conditions were 30 sec at 95°C, 30 sec at 62°C and 30 sec at 72°C for 40 cycles, and a final extension at 72°C for 5 min.

### Western blot analysis

For western blot analysis, cells (5×10^4^/well) were seeded in 6-well culture plates and incubated in a CO~2~ incubator at 37°C until they reached 30% confluence. Subsequently, cells were transfected with pGCSIL-shOIP5 lentivirus or pGCSIL-shCtrl lentivirus, according to the aforementioned protocol, and continuously incubated for 120 h. Subsequently, cells were lysed using ice-cold lysis buffer (100 mM Tris, pH 6.8 2% b-mercaptoethanol, 20% glycerol and 4% SDS). The lysates were centrifuged for 10 min at 12,000 × g and 4°C, and then the supernatants were collected and the protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.). According to Laemmli\'s method ([@b23-or-41-04-2075]), equal amounts (20 µg) of proteins from each sample were separated by 10% SDS-PAGE, and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Membranes were incubated in 5% skimmed milk diluted by TBST (25 mM Tris, pH 7.4, 0.1% Tween-20, 150 mM NaCl) for 1 h at room temperature. Subsequently, membranes were incubated overnight at 4°C with the following primary antibodies: Rabbit polyclonal anti-OIP5 (ProteinTech Group, Inc. Chicago, IL, USA; cat no. 12142--1-AP; 1:500 dilution), mouse monoclonal anti-Flag M2 (Sigma-Aldrich; Merck KGaA; cat no. F1804; 1:1,000 dilution), mouse polyclonal anti-bone morphogenetic protein receptor type 2 (BMPR2; Abcam; cat no. ab130206; 1:200 dilution), rabbit monoclonal anti-JUN (Abcam; cat no. ab32137; 1:1,000 dilution), rabbit anti-cullin 4B (Abcam; cat no. ab85610; 1:1,000 dilution), mouse monoclonal anti-checkpoint kinase 1 (CHEK1; Cell Signaling Technology, Inc., Danvers, MA, USA; cat no. \#2360S; 1:1,000 dilution), rabbit polyclonal anti-Rac family small GTPase 1 (RAC1; Abcam; cat no. ab97568; 1:500 dilution), rabbit monoclonal anti-baculoviral IAP repeat containing 3 (Abcam; cat no. ab32059; 1:1,000 dilution) or mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat no. sc-32233; 1:2,000 dilution). Finally, goat anti-mouse (Santa Cruz Biotechnology, Inc.; cat no. sc-2005; 1:5,000 dilution) or goat anti-rabbit horseradish peroxidase (Santa Cruz Biotechnology, Inc.; cat no. sc-2004; 1:5,000 dilution) secondary antibodies were used for 1 h at 37°C. Signals were detected using an Enhanced Chemiluminescent-PLUS/kit (GE Healthcare Life Sciences, Little Chalfont, UK; cat no. RPN2132), according to the manufacturer\'s protocols. GAPDH was used as internal control.

### MTT assay

Proliferation of HepG2 and Huh7 cells transfected with pGCSIL-shOIP5 or pGCSIL-shCtrl plasmid was determined using an MTT assay. Transfected HepG2 and Huh7 cells (1,000 cells/100 µl/well) within the logarithmic phase were seeded in 96-well culture plates and incubated at 37°C in an atmosphere containing 5% CO~2~ for 5 days. Subsequently, 10 µl MTT (5 mg/ml; Beijing Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China) was added to each well, and incubated at 37°C for 4 h at the end of the incubation time. Afterwards, the supernatant was discarded, and 100 µl dimethyl sulfoxide (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) were added to each well, and incubated at 37°C for 10 min in an air bath shaker. The absorbance was measured at 490 nm using an ELx800 microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

### Colony formation assay

The effect of OIP5 knockdown on colony formation following pGCSIL-shOIP5 transfection was determined in parallel with the effect following transfection with pGCSIL-shCtrl. Transfected Huh7 and HepG2 cells (1,000 cells/well) were seeded in a 6-well culture plates and incubated at 37°C for 10 days to form colonies. DMEM was replaced every 2 days with fresh DMEM containing 10% FBS and 1% penicillin-streptomycin. Cells were washed with PBS three times (pH 7.2) and fixed with 4% paraformaldehyde (Sangon Biotech Co., Ltd.) at room temperature for 30 min. The fixed cells were washed with PBS three times and stained with 100 µl Giemsa staining solution (Chemicon International; Thermo Fisher Scientific, Inc.) at room temperature for 20 min. The total number of colonies containing \>50 cells was calculated under an optical microscope (magnification, ×400).

### Cell cycle and apoptosis analysis

The proportion of cells at each cell cycle stage or undergoing apoptosis was inspected by flow cytometry (FCM) following OIP5 knockdown. After 4 days post-lentiviral infection, HepG2 and Huh7 cells were seeded in 6-cm dishes (1×10^6^ cells/dish). Cells were harvested when the coverage rate of cells was \>70%, and subsequently fixed with 70% ice ethanol for 1 h at 4°C. Cells were then washed with PBS three times (pH 7.2), treated with 1.5 ml PBS containing 50 µg/ml propidium iodide (Sigma-Aldrich; Merck KGaA; cat no. P4170) and 100 µg/ml RNase A (Fermentas; Thermo Fisher Scientific, Inc.; cat no. EN0531), and incubated in the dark at room temperature for 30 min. The suspension was filtered using a 300-mesh and then subjected to FCM with a FACS Calibur flow cytometer (BD Biosciences; Becton Dickinson and Company, Franklin Lakes, NJ, USA) to determine cell cycle phases. The data were analyzed by WinMDI v2.9 software (The Scripps Research Institute, San Diego, CA, USA). All experiments were executed in triplicate. To identify cells undergoing apoptosis, Huh7 and HepG2 cells were cultured with DMEM containing 10% FBS and 1% penicillin-streptomycinin6-well culture plates (5×10^4^ cells/4 ml/well) at 37°C. After 5 days post-lentiviral infection, transfected cell lines were collected and washed with ice-cold PBS three times (pH 7.4). Subsequently, cell concentrations were adjusted to 1×10^6^ cells/ml using 1X binding buffer (eBioscience; Thermo Fisher Scientific, Inc.; cat no. 88-8007). Cell suspension (100 µl) were stained with 5 µl Annexin V-APC (eBioscience; Thermo Fisher Scientific, Inc.; cat no. 88-8007) and incubated in the dark for 10--15 min at room temperature. Cells were analyzed by FCM with a flow cytometer within 1 h. All experiments were executed in triplicate.

### RNA isolation and microarray analysis

The expression status of 20,000 genes was determined in Huh7 cells transfected with pGCSIL-shOIP5 or pGCSIL-shCtrl lentiviruses. Initially, RNA was isolated from Huh-7 cells 72 h post transfection using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and the RNA quality was evaluated using a NanoDrop 2000 spectrophotometer and Agilent Bioanalyzer 2100. Individual microarrays of gene expression profiles (GeneChipPrimeview Human Gene Expression Array; cat no. 901838; Affymetrix; Thermo Fisher Scientific, Inc.) were used for each sample of the transfected cells aforementioned. Concisely, 0.5 µg RNA were used to synthesize cDNA. Reverse transcription was performed using a High Capacity RNA-to-cDNA kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Biotin-labeled amplified RNA was synthesized from a double-stranded cDNA using the GeneChip 3′ IVT labeling kit (Affymetrix; Thermo Fisher Scientific, Inc.). The wash and staining protocols were performed using a GeneChip Hybridization Wash and Stain kit and GeneChip Fluidics Station 450 (both from Affymetrix; Thermo Fisher Scientific, Inc.), respectively, according to the manufacturer\'s protocols. Finally, the probe arrays were scanned using a GeneChip Scanner 3000 (Affymetrix; Thermo Fisher Scientific, Inc.).

### Microarray data normalization and analysis

GeneSpring v11 software (Agilent Technologies, Inc.) was used to analyze microarray data. Initially, data associated withpGCSIL-shOIP5- and pGCSIL-shCtrl-transfected cells were normalized using GeneSpring normalization algorithms. Genes differentially expressed by at least ±1.5-fold were determined as statistically significant (P\<0.05), according to the Student\'s t-test based on the normalized data, relative to the negative control. A series of transcripts that were differentially expressed as a function of the transfection was produced, and they were hierarchically clustered based on certain associations. Enriched pathways were determined using Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) and Ingenuity Pathway Analysis (IPA; <http://www.qiagen.com/ingenuity>). Finally, gene sets with significantly different expression levels were used to identify molecular functions by RT-qPCR and western blotting, as aforementioned. The primers used to perform RT-qPCR are listed in [Table II](#tII-or-41-04-2075){ref-type="table"}.

### Tumorigenesis in nude mice

A total number of 20 female BALB/c nude mice, 4-week old, weighing 20±2 g were purchased at Shanghai GeneChem Co., Ltd. Mice were kept in a pathogen-free animal facility at a 12:12-h light-dark cycle at a constant temperature of 23±1°C and humidity of 50±1%, fed with a standard diet. All mice were bred according to the experimental animal care and research protocol, which was approved by the Ethics Committee of the Institutional Review Board of the Nanjing Medical University on Animal Experiments (Nanjing, China). Tumorigenesis in nude mice was determined as previously described ([@b24-or-41-04-2075]). Briefly, Huh7 cells successfully transfected with pGCSIL-shOIP5 or pGCSIL-pGCSIL-shCtrl lentivirus were subcutaneously injected into the mice abdomen at a single site. The tumor size was determined using a caliper of the excised neoplasm at the time of execution. The animals were sacrificed by cervical dislocation at 4 weeks after injection. All experiments on mice were performed in accordance with the Guide for the Care and Use of Laboratory Animals ([@b25-or-41-04-2075]) and approved by the Ethics Committee of the Institutional Review Board of the Nanjing Medical University on Animal Experiments.

### Statistical analyses

Data were analyzed by SPSS v16 (SPSS, Inc., Chicago, IL, USA). All categorical data are indicated as a frequency. The associations between OIP5 expression in the human samples and clinical variables were analyzed using the χ^2^ test. The association between OIP5 expression in tumors and patient disease-specific survival rate was fitted with Kaplan-Meier survival curves and assessed with the log-rank test. A Cox proportional hazards model was fitted for multivariable analysis. Quantitative data are presented as the mean ± standard deviation. Statistical analyses were performed using unpaired Student\'s t-test and one-way analysis of variance followed by Dunnett\'s tests. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### OIP5 expression in tumor and non-tumor adjacent tissue

Firstly, the online database GEPIA was used to investigate OIP5 mRNA differential expression between liver cancer and normal liver tissues. GEPIA data analysis indicated that OIP5 mRNA expression was significantly increased in liver cancer tissues, compared with normal liver tissues (P\<0.05; [Fig. 1A](#f1-or-41-04-2075){ref-type="fig"}). To verify these results, OIP5 expression in liver tissue was evaluated through IHC staining. As depicted in [Fig. 1B](#f1-or-41-04-2075){ref-type="fig"}, OIP5 staining was brown, particularly in the tumor cytoplasm. The positive rate of OIP5 expression in carcinoma tissues was notably increased, compared with non-cancerous tissue. Subsequently, the characteristics of patients recruited, including age, sex, tumor size, pathological grading and TNM stage, were summarized and analyzed. As depicted in [Table I](#tI-or-41-04-2075){ref-type="table"}, there was no significant difference in OIP5 expression between early and late stage HCC. Finally, the online tool Kaplan-Meier plotter was used to analyze the association between OIP5 expression and the prognosis of patients. It was observed that the survival rate of patients with high OIP5 expression was significantly reduced, compared with those with low OIP5 expression (P\<0.01, [Fig. 1C](#f1-or-41-04-2075){ref-type="fig"}).

### OIP5 endogenous expression in liver cancer cell lines and PHH cells

As depicted in [Fig. 2](#f2-or-41-04-2075){ref-type="fig"}, endogenous OIP5 expression was significantly increased in Huh7 and HepG2 cell lines, compared with PHH cells (P\<0.01). Western blotting confirmed OIP5 protein expression in those cells. These data indicated that OIP5 is highly expressed in liver cancer cell lines.

### Effect of pGCSIL-shOIP5 lentivirus transfection on OIP5 expression in Huh7 and HepG2 cell lines

Huh7 and HepG2 cell lines were infected with lentivirus-pGCSIL-shOIP5 and lentivirus-pGCSIL-shCtrl. As depicted in [Fig. 3A](#f3-or-41-04-2075){ref-type="fig"}, Huh7 and HepG2 cells were successfully transfected with pGCSIL-shOIP5/pGCSIL-shCtrl lentivirus. To investigate the knockdown effect of the pGCSIL-shOIP5 lentivirus, OIP5 expression in the Huh7 and HepG2 cell lines were quantified by RT-qPCR and western blot analysis. OIP5 mRNA expression was significantly decreased by pGCSIL-shOIP5 lentivirus transfection in Huh7 and HepG2 cell lines, compared with pGCSIL-shCtrl lentivirus transfection (P\<0.01; [Fig. 3B](#f3-or-41-04-2075){ref-type="fig"}). As depicted in [Fig. 3C](#f3-or-41-04-2075){ref-type="fig"}, OIP5 protein expression was also inhibited by pGCSIL-shOIP5 lentivirus transfection in Huh7 and HepG2 cell lines, which identified that the GCSIL-shOIP5 lentivirus could effectively silence the target gene.

### Effect of OIP5 knockdown in liver cancer cell lines on cell proliferation

As depicted in [Fig. 4A](#f4-or-41-04-2075){ref-type="fig"}, and determined by quantification in [Fig. 4B](#f4-or-41-04-2075){ref-type="fig"}, the number of Huh7 cells transfected with pGCSIL-shCtrl lentivirus significantly increased over the 5 days of observation, while the number of pGCSIL-shOIP5-transfected Huh7 cells remained almost the same. The proliferation activity was examined using an MTT assay and expressed as optical density 490 nm. As depicted in [Fig. 4C](#f4-or-41-04-2075){ref-type="fig"}, the proliferative effect of Huh7 cells transfected with pGCSIL-shCtrl was increased, compared with Huh7 cells transfected with pGCSIL-shOIP5 (P\<0.01). Additionally, the results were further confirmed in HepG2 cells ([Fig. 4D-F](#f4-or-41-04-2075){ref-type="fig"}). These data indicated that the proliferation of Huh7 or HepG2 cells could be significantly suppressed by OIP5 knockdown.

### Effect of OIP5 knockdown on colony formation

Impairment of colony formation between pGCSIL-shOIP5-transfected Huh7 cells and pGCSIL-shCtrl-transfected Huh7 cells was observed, as depicted in [Fig. 5A](#f5-or-41-04-2075){ref-type="fig"}. Furthermore, when counted, OIP5-knockdown Huh7 cells colony numbers were significantly reduced, compared with the number in the controls with functional OIP5 (P\<0.01; [Fig. 5B](#f5-or-41-04-2075){ref-type="fig"}). Similarly, OIP5 knockdown significantly affected the colony formation of HepG2 cells (P\<0.01; [Fig. 5C and D](#f5-or-41-04-2075){ref-type="fig"}). These data indicated that silencing of OIP5 expression could inhibit colony forming in liver cancer cells.

### Effect of OIP5 knockdown in liver cancer cells on the cell cycle

OIP5 knockdown significantly decreased the number of cells in the S phase, and significantly increased the number of cells in the G~0~/G~1~ phases in HepG2 and Huh7 cells (P\<0.05, [Fig. 6](#f6-or-41-04-2075){ref-type="fig"}). These results indicated that those cells were arrested following OIP5 gene knockdown and OIP5 was strongly associated with cell cycle distribution.

### Effect of OIP5 knockdown in liver cancer cells on apoptosis

As depicted in [Fig. 7](#f7-or-41-04-2075){ref-type="fig"}, cell apoptosis was significantly increased in cells following OIP5 knockdown, compared with the control cells with OIP5 intact expression (P\<0.05). These data indicated that silencing OIP5 promoted the apoptosis of liver cancer cells, including HepG2 and Huh7 cells.

### Effect of OIP5 knockdown in Huh7 cells on gene expression

A total of 20,000 genes were analyzed by microarray to determine the influence of OIP5 knockdown on downstream gene expression. A total number of 628 genes were differentially expressed in OIP5 knockdown Huh7 cells, compared with control Huh7 cells (±2.0-fold change; P\<0.05), 87 of which were upregulated, whilst the remaining 541 were downregulated. Hierarchical clustering of the microarray data was depicted in [Fig. 8A](#f8-or-41-04-2075){ref-type="fig"}. Biological interactions were identified in the 628 DEGs using IPA and KEGG pathway analysis. Of these networks, a list of the top 10 networks was depicted in [Fig. 8B](#f8-or-41-04-2075){ref-type="fig"}, and those genes associated with 'RNA Post-Transcriptional Modification, Cancer, Organismal Injury and Abnormalities' were part of the highest ranked network. [Fig. 8C](#f8-or-41-04-2075){ref-type="fig"} depicts that OIP5 is located upstream of all focus genes.

### Effect of OIP5 knockdown in Huh7 cells on BMPR2/JUN/CHEK1/RAC1

To understand the molecular mechanisms underlying OIP5-mediated cancer growth, apoptotic genes mRNA expression was evaluated in liver cancer cells following OIP5 knockdown. As depicted in [Fig. 9A](#f9-or-41-04-2075){ref-type="fig"}, OIP5 may affect the growth or apoptosis of Huh7 cells through the microRNA-1/heterogeneous nuclear ribonucleoprotein U (HNRNPU) and cyclin dependent kinase inhibitor 2A/eukaryotic translation elongation factor 1α1 (EEF1A1)/mitotic arrest deficient 2 like 1 (MAD2L1) pathways. RT-qPCR analyses were further performed to evaluate downstream gene expression, and it was determined that JUN, RAC1, MAD2L1, HNRNPU and EEF1A1 mRNA expression was significantly decreased following OIP5 knockdown, while BMPR2 and CHEK1 were significantly upregulated. Furthermore, it was identified via western blotting that OIP5 knockdown markedly altered the expression of proteins, including as JUN, RAC1, BMPR2 and CHEK1 ([Fig. 9B and C](#f9-or-41-04-2075){ref-type="fig"}). Collectively, these results indicated that OIP5 was involved in the growth and apoptosis of liver cancer cells via dysregulation of RAC1/JUN/BMPR2/CHEK1.

### OIP5 knockdown inhibits tumorigenicity of HCC in vivo

To examine the effects of OIP5 knockdown on tumor growth *in vivo*, Huh7 cells transfected with pGCSIL-shCtrl (control group) or pGCSIL-shOIP5 lentiviruses were transplanted into BALB/c nude mice. Control cells formed tumors in 22 days after implantation, while Huh7 cells transfected with pGCSIL-shOIP5 lentivirus failed to proliferate by 22 days after implantation. As depicted in [Fig. 10A and B](#f10-or-41-04-2075){ref-type="fig"}, shOIP5 treatment significantly reduced tumor size and weight, compared with the control group. The bioluminescence images were observed and analyzed in those nude mice at 4 weeks after Huh7 cells implantation. It was determined that the bioluminescent tumor xenografts exhibited a reduced growth rate in the shOIP5 treatment group, compared with the control mice ([Fig. 10C](#f10-or-41-04-2075){ref-type="fig"}). Thus, these data indicated that OIP5 knockdown could have an inhibitory effect on liver cancer cell growth and tumorigenicity, suggesting a potential therapeutic approach against liver cancer in which OIP5 is overexpressed.

Discussion
==========

Despite rapid progress in surgical techniques, which are the primary therapies for liver cancer, combined with adjuvant chemotherapy or radiotherapy, patients with liver cancer frequently relapse following liver resection ([@b3-or-41-04-2075]). In order to prevent recurrence and treat, for patients who cannot be surgically treated or cannot tolerate radiotherapy and chemotherapy, it is urgent to clarify the mechanism of liver cancer progression to develop novel therapeutic targets highly specific to malignant cells, and have minimal or no risk of adverse effects.

OIP5 is necessary for the recruitment of centromere protein A through the mediator Holiday junction recognition protein ([@b8-or-41-04-2075],[@b9-or-41-04-2075],[@b26-or-41-04-2075]). Human OIP5 protein has been first identified using the yeast two-hybrid system ([@b27-or-41-04-2075]). The OIP5 protein sequence in human epithelial cells is the same as that of human testis protein ([@b27-or-41-04-2075]). As previously reported, the gene is conserved in genome of chimpanzee, Rhesus monkey, cow, dog, chicken and mouse ([@b27-or-41-04-2075]).

OIP5 belongs to CTAs, and it is immunogenic, highly specific to cancer and is rarely expressed in the majority of normal tissues; however, it is frequently presented in various cancer types, including lung, breast and esophageal cancer ([@b28-or-41-04-2075]). Those characteristics make CTAs promising candidates for cancer immunotherapy ([@b28-or-41-04-2075]). CTAs are divided into two subclasses according to the chromosomal localization of their coding genes, which are chromosome X-encoded CTAs and autosomal-encoded CTAs ([@b28-or-41-04-2075]). OIP5 is an autosomal-encoded CTA ([@b27-or-41-04-2075]). A number of papers have reported that CTAs commonly act as oncogenes involved in tumor progression ([@b29-or-41-04-2075],[@b30-or-41-04-2075]). OY-YES-1, a CTAs homolog of human OIP5, is overexpressed in HCC and its inhibition weakens malignant behaviors of liver cancer cells, including cell growth, cell apoptosis, cell migration and cell metastasis, and then results in cell cycle arrest by regulating caspase-3, matrix metallopeptidase 2 (MMP2), MMP9 and reducing cyclic E expression ([@b30-or-41-04-2075]).

OIP5 aberrant expression is common in various types of cancer, including glioblastoma ([@b31-or-41-04-2075]), bladder cancer ([@b32-or-41-04-2075],[@b33-or-41-04-2075]), acute myeloid leukemia ([@b14-or-41-04-2075]), lung, esophageal ([@b15-or-41-04-2075]) and breast cancer ([@b34-or-41-04-2075],[@b35-or-41-04-2075]), clear cell renal cell carcinoma ([@b11-or-41-04-2075]), gastric and colorectal cancer ([@b12-or-41-04-2075],[@b13-or-41-04-2075]), and HCC ([@b16-or-41-04-2075]). Additionally, He *et al* ([@b32-or-41-04-2075]) reported that the expression of OIP5 was markedly positively associated with sex, tumor size, high-grade tumor and T classification. Compared with the patients with low OIP5 expression, patients with high OIP5 expression had reduced survival time. In lung and esophageal carcinogenesis, increased expression of OIP5 predicts a reduced patients\' overall survival time ([@b15-or-41-04-2075]). OIP5 expression is also considered to be positively associated with lymphatic metastasis in esophageal carcinoma ([@b15-or-41-04-2075]). As reported by Gong *et al* ([@b11-or-41-04-2075]), the upregulation of OIP5 in patients with clear cell renal cell carcinoma was positively associated with the Fuhrman grade, T classification, N classification and clinical stage, therefore patients with increased expression of OIP5 exhibited a reduced survival rate. The present data demonstrated that OIP5 is also highly expressed in liver cancer tissues, based on bioinformatics and IHC staining, and patients with liver cancer with a high expression of OIP5 exhibited a markedly decreased overall survival rate, compared with those with low OIP5 expression.

OIP5 is involved in the cell progression of a number of cancer types, including bladder, lung and esophageal cancer, due to its action on cell proliferation, inhibition of cell apoptosis and arrest of the cell cycle ([@b15-or-41-04-2075],[@b32-or-41-04-2075],[@b33-or-41-04-2075]). Silencing of OIP5 expression suppressed the colony-forming ability and inhibited tumor cell growth in bladder cancer ([@b32-or-41-04-2075]). In lung cancer, esophageal cancer and clear cell renal cell carcinoma, OIP5 down regulation notably depresses cell survival and the colony-forming ability, while restoration of OIP5 expression stimulates cell growth ([@b11-or-41-04-2075],[@b15-or-41-04-2075]). Silencing OIP5 expression also inhibits proliferation of gastric and colorectal cancer cells *in vitro* ([@b12-or-41-04-2075]). Furthermore, OIP5 is overexpressed in obese adipose tissues, where it promotes pre- and mature-adipocytes proliferation and causes the occurrence of fatty hyperplasia ([@b36-or-41-04-2075]). In the present study, it was identified that OIP5 knockdown inhibited cell proliferation, reduced colony formation and also arrested the cell cycle at the G~0~/G~1~ or G~2~/M phases in liver cancer cells. Furthermore, OIP5 knockdown promoted the apoptosis of those cells. It was considered that cell apoptosis as an important physiological process is associated with the formation of a variety of tumor types ([@b34-or-41-04-2075],[@b37-or-41-04-2075]). Thus, the aforementioned results indicated that OIP5 had important roles in the formation of liver cancer.

In order to identify the molecular mechanisms of OIP5-mediated liver cancer progression, the expression profiles of 20,000 genes following OIP5 knockdown in Huh7 cells was determined. OIP5 knockdown in Huh7 cells resulted in the deregulation of 628 genes, 87 of which were upregulated while the remaining 541 were downregulated. Enriched pathways were determined using KEGG and IPA, and it was identified that those differentiated genes were primarily involved in RNA post-transcriptional modification and cell proliferation. Expression data integration at the mRNA and protein levels demonstrated that OIP5 knockdown decreased the expression levels of RAC1. As a member of the Rho family of small GTPases, RAC1 serves a major role in the reactive oxygen species (ROS)-producing NADPH oxidases, which are involved in ROS-dependent signaling ([@b38-or-41-04-2075]--[@b40-or-41-04-2075]). The present results indicated that OIP5 silencing may be involved in ROS production, which resulted in liver cancer cell apoptosis.

In conclusion, the present results demonstrated the OIP5 involvement in the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation, providing a potential biomarker in liver cancer diagnosis and targeted therapy.
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![Protein expression of OIP5 in HCC tissues and non-tumor adjacent tissues and overall survival curves analysis. (A) OIP5 mRNA overexpression in liver cancer predicted by Gene Expression Profiling Interactive Analysis. (B) Representative pictures of immunohistochemistry analysis of OIP5 protein in primary HCC T and NT tissues (magnification, ×400). (C) The association between overall survival time and differential OIP5 expression in HCC was analyzed by a Kaplan-Meier survival curve. \*P\<0.05. T, tumor; NT, non-cancerous; OIP5, Opa interacting protein 5; HR, hazard ratio; N, non-tumor; HCC, hepatocellular carcinoma; LIHC, liver hepatocellular carcinoma.](OR-41-04-2075-g00){#f1-or-41-04-2075}

![OIP5 endogenous expression in liver cancer cell lines and PHH. (A) Endogenous OIP5 mRNA expression in Hep3B, Huh7, HepG2 and PHH cells analyzed by reverse transcription-quantitative polymerase chain reaction. GAPDH was used as an internal control for normalization. \*\*P\<0.01 and \*\*\*P\<0.001 vs. the PHH group. (B) OIP5 protein expression in four liver cancer cell lines and PHH cells by western blotting analysis. GAPDH was used as an internal control. PHH, primary human hepatocyte; OIP5, Opa interacting protein 5.](OR-41-04-2075-g01){#f2-or-41-04-2075}

![OIP5 expression in both in Huh7 and HepG2 cells following OIP5 knockdown. (A) Transfection efficacy following lentivirus transfection using pGCSIL-shOIP5, and pGCSIL-shCtrl as the control (magnification, ×400). (B) OIP5 mRNA expression in Huh7 and HepG2 cells by reverse transcription-quantitative polymerase chain reaction. (C) OIP5 protein expression in Huh7 and HepG2 cells by western blotting. GAPDH was used as the internal control. \*\*P\<0.01 vs. the pGCSIL-shCtrl group. Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g02){#f3-or-41-04-2075}

![The effect of OIP5 knockdown on Huh7 and HepG2 proliferation. (A) After Huh7 cells was transfected with pGCSIL-shOIP5 or pGCSIL-shCtrl lentivirus, the representative fluorescence microscope images were collected at each day (magnification, ×200). (B) The cell counts of Huh7 were measured using an automated cell counter at each day post-infection (pGCSIL-shCtrl vs. pGCSIL-shOIP5 at day 5; \*\*\*P\<0.001). (C) The proliferation of Huh7 cells was measured with an MTT assay at each day post-infection (pGCSIL-shCtrl vs. pGCSIL-shOIP5 at day 5; \*\*P\<0.01). (D) After HepG2 cells was transfected with pGCSIL-shOIP5 or pGCSIL-shCtrl lentivirus, the representative fluorescence microscope images were collected at each day (magnification, ×200). (E) The cell counts of HepG2 were measured using an automated cell counter at each day post-infection (pGCSIL-shCtrl vs. pGCSIL-shOIP5 at day 5; \*\*P\<0.01). (F) The proliferation of HepG2 cells was measured with an MTT assay at each day post-infection (pGCSIL-shCtrl vs. pGCSIL-shOIP5 at day 5; \*\*P\<0.01). Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5; OD, optical density.](OR-41-04-2075-g03){#f4-or-41-04-2075}

![The effect of OIP5 knockdown on colony formation of Huh7 and HepG2 cells. (A) Photomicrographs of green fluorescent protein-expressing colonies of Huh7 cells in 6-well culture plates (magnification, ×400). (B) Mean number of Huh7 cells in each well, \*\*P\<0.01 vs. the pGCSIL-shCtrl group. (C) Photomicrographs of green fluorescent protein-expressing colonies of HepG2 cells in 6-well culture plates (magnification, ×400). (D) Mean number of HepG2 cells in each well, \*\*P\<0.01 vs. the pGCSIL-shCtrl group. Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g04){#f5-or-41-04-2075}

![The effect of OIP5 knockdown on the cell cycle of Huh7 and HepG2 cells. (A) Cell cycle analysis of Huh7 cells by flow cytometry. (B) Different cell cycle phases percentages of Huh7 cells. (C) Cell cycle analysis of HepG2 cells by flow cytometry. (D) Different cell cycle phases percentages of HepG2 cells. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. the pGCSIL-shCtrl group. Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g05){#f6-or-41-04-2075}

![The effects of OIP5 knockdown on cell apoptosis. (A) Annexin V staining and flow cytometry were used to detectthe apoptosis of Huh7 cells. (B) Apoptosis was significantly increased in Huh7 cells transfected with pGCSIL-shOIP5, compared with the negative control. (C) Annexin V staining and flow cytometry were used to detect the apoptosis of HepG2 cells. (D) Apoptosis was significantly increased in HepG2 cells transfected with pGCSIL-shOIP5, compared with the negative control. \*P\<0.05 and \*\*P\<0.01 vs. the pGCSIL-shCtrl group. Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g06){#f7-or-41-04-2075}

![IPA summary of DEGs derived from Affymatrix human GeneChip PrimeView containing 20,000 genes. (A) Heatmap of DEGs derived from the microarray. (B) Top 10 networks with their respective scores obtained using IPA. (C) The highest rated network (RNA Post-Transcriptional Modification, Cancer, Organismal Injury and Abnormalities) in IPA. Downregulated genes are depicted in green, whereas upregulated genes are depicted in red. DEGs, differentially-expressed genes; Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g07){#f8-or-41-04-2075}

![The effect of OIP5 knockdown on downstream genes. (A) Analysis of downstream genes of OIP5 using IPA analysis. (B) RT-qPCR was used to determine the changes in the expression of OIP5 downstream genes in Huh7 cells at 72 h following pGCSIL-shOIP5 transfection. Samples were normalized to GAPDH mRNA expression. RT-qPCR results are indicated as mean ± standard deviation of three independent experiments performed in triplicate. GAPDH protein was used as the internal control. \*P\<0.05 and \*\*P\<0.01 vs. pGCSIL-shCtrl-transfected cells. (C) The expression of OIP5 downstream proteins were analyzed by western blot analysis in Huh7 cells transfected with pGCSIL-shOIP5 lentivirus. ^\#^, target genes with a Z-score \>3.0; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5; mir-1, microRNA1; CDKN2A, cyclin dependent kinase inhibitor 2A; TWF1, twinfilin actin binding protein 1; H3F3A, H3 histone family member 3A; HNRNPU, heterogeneous nuclear ribonucleoprotein U; EEF1A1, eukaryotic translation elongation factor 1α1; RB1, retinoblastoma 1; MAD2L1, mitotic arrest deficient 2 like 1; BTG2, B-cell translation gene 2; BMPR2, bone morphogenetic protein receptor type 2; CHEK1, checkpoint kinase 1; RAC1, Rac family small GTPase 1; PDIA3, protein disulfide isomerase family A member 3; RPS6KB1, ribosomal protein S6 kinase B1; CUL4B, cullin 4B.](OR-41-04-2075-g08){#f9-or-41-04-2075}

![OIP5 knockdown inhibits tumorigenicity of hepatocellular carcinoma cells *in vivo*. BALB/c nude mice were subcutaneously injected with Huh7 cells transfected with pGCSIL-shCtrl or pGCSIL-shOIP5 lentivirus. (A) Tumor volumes were measured on the indicated days (shCtrl vs. shOIP5 group, \*\*\*P\<0.001). (B) Tumor weight was measured at 4 week following injection (shCtrl vs. shOIP5 group, \*\*P\<0.01). (C) Representative bioluminescent imaging of Huh7 cells implanted at 4 weeks after injection, n=10. Ctrl, control; sh, short hairpin; OIP5, Opa interacting protein 5.](OR-41-04-2075-g09){#f10-or-41-04-2075}

###### 

Association between OIP5 expression and clinicopathological parameters of patients with liver cancer.

                                                    OIP5 expression levels                
  ------------------------------------------- ----- ------------------------ ---- ------- -------
  Age (years)                                                                             
    \<60                                      57    41                       16   0.753   0.386
    ≥60                                       18    11                       7            
  Sex                                                                                     
    Male                                      62    41                       21   0.967   0.325
    Female                                    13    11                       2            
  Tumor size (cm)                                                                         
    \<3                                       18    15                       3    0.671   0.413
    ≥3                                        57    37                       20           
  Pathological grade ([@b18-or-41-04-2075])                                               
    I--II                                     69    49                       20   0.371   0.542
    III                                         6     3                      3            
  TNM stage ([@b19-or-41-04-2075])                                                        
    I--II                                     45    33                       12   0.847   0.358
    III--IV                                   30    19                       11           

TNM, tumor-node-metastasis; OIP5, Opa interacting protein 5.

###### 

Primer sequences used for reverse transcription-quantitative polymerase chain reaction.

  Gene         Primer sequence 5′-3′     Fragment length (bp)
  ------------ ------------------------- ----------------------
  RPS6KB1 FP   TGTTGCTTCTGAATCACTGTTG    154
  RPS6KB1 RP   GTCTTTGCTTCCATTTTGCTG     
  BMPR2 FP     ACGGGTATCTTTTGTTGGTGT     213
  BMPR2 RP     TGTCAGCTTTCATAGTGGCATC    
  CHEK1 FP     ACCTGCTTTACATTTCCACTTG    174
  CHEK1 RP     ACAGCAAACAGAGGAGGTTATT    
  CUL4B FP     TCTAACTCATCCCTGATGGTCT    234
  CUL4B RP     TTAAACAGCTCCCCTCAACTT     
  JUN FP       ATGGTCAGGTTATACTCCTCCTC   164
  JUN RP       CACATGCCACTTGATACAATCC    
  RAC1 FP      GTAGCAGCTCAGCTCTTTGGA     228
  RAC1 RP      TACCCGTGACACTTTCATTCC     
  HNRNPU FP    TACCAAATAAGCAACAGGGAG     249
  HNRNPU RP    AAGCCAGTTTACACTCAGCAT     
  MAD2L1 FP    TTCTTCTCATTCGGCATCAAC     229
  MAD2L1 RP    TTTCCAGGACCTCACCACTTT     
  EEF1A1 FP    GGGATGGAAAGTCACCCGTAA     104
  EEF1A1 RP    GCAAGGGCTTGTCAGTTGGAC     
  PDIA3 FP     ATTTCGTCCTTCACATCTCAC     243
  PDIA3 RP     ACCATCATTACCCTGTTTCTC     
  GAPDH FP     TGACTTCAACAGCGACACCCA     121
  GAPDH RP     CACCCTGTTGCTGTAGCCAAA     

FP, forward primer; RP, reverse primer; RPS6KB1, ribosomal protein S6 kinase B1; BMPR2, bone morphogenetic protein receptor type 2; CHEK1, checkpoint kinase 1; CUL4B, cullin 4B; RAC1, Rac family small GTPase 1; HNRNPU, heterogeneous nuclear ribonucleoprotein U; MAD2L1, mitotic arrest deficient 2 like 1; EEF1A1, eukaryotic translation elongation factor 1α1; PDIA3, protein disulfide isomerase family A member 3.
